"
Team:ESBS-Strasbourg/10 July 2008
From 2008.igem.org
(Difference between revisions)
(→WetLab) |
|||
| (One intermediate revision not shown) | |||
| Line 2: | Line 2: | ||
== DryLab == | == DryLab == | ||
* MM: Sponsoring | * MM: Sponsoring | ||
| + | * michi: | ||
| + | ** design of the oligos to construct the operons of our DNA Binding Proteins. | ||
| + | ** design of the promoter region: get CMV minimal promoter | ||
=== Modeling === | === Modeling === | ||
| Line 10: | Line 13: | ||
** Transformation (db3.1) with positive and negative control and BB_p1010 in Amipicillin and in Kanamycin backround | ** Transformation (db3.1) with positive and negative control and BB_p1010 in Amipicillin and in Kanamycin backround | ||
* Sandra: | * Sandra: | ||
| - | ** | + | ** resuspension of primers to stock solutions of 50 µM |
** making primer aliquots of 10 µM (4x 50 µl) | ** making primer aliquots of 10 µM (4x 50 µl) | ||
| - | ** transformation (dh5alpha cells) with | + | ** transformation (dh5alpha cells) with positive and negative control and BioBrick GFP-device |
* MM: | * MM: | ||
** TSB-Buffer | ** TSB-Buffer | ||
Latest revision as of 12:26, 16 July 2008
Contents |
DryLab
- MM: Sponsoring
- michi:
- design of the oligos to construct the operons of our DNA Binding Proteins.
- design of the promoter region: get CMV minimal promoter
Modeling
WetLab
- Katja:
- Preparation of LB liquid media and LB(A) plates
- Transformation (db3.1) with positive and negative control and BB_p1010 in Amipicillin and in Kanamycin backround
- Sandra:
- resuspension of primers to stock solutions of 50 µM
- making primer aliquots of 10 µM (4x 50 µl)
- transformation (dh5alpha cells) with positive and negative control and BioBrick GFP-device
- MM:
- TSB-Buffer
- Made competent cells (TOP10, db3.1, dh5alpha)
- Transformation (TOP10)
General
Quote of the day
MW: "I always got heavy beard growth -roarr"
